Opus Genetics (IRD) reports inducement awards

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LVS
6. SAP
7. CSX
8. LRCX
9. ELV
10. NDAQ

Go back to Opus Genetics (IRD) reports inducement awards

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

March 19, 2025 3:56 PM EDT

RESEARCH TRIANGLE PARK, N.C., March 19, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing important new therapies for the treatment of inherited retinal diseases (IRDs) and other ophthalmic disorders (Opus or the Company), today announced that the independent members of its Board of Directors approved equity awards under the Companys 2021 Inducement Plan, as amended, as a material inducement to two new employees in connection with the commencement of their employment with the Company effective March 13, 2025. The equity awards were approved in accordance with Nasdaq Listing rule 635(c)(4),... More